Checkout

PBD Biotech is one of the finalists selected to participate in the 42plus1 pitch event at DxPx EU in Munich, Germany on the 5th October 2023. This follows our participation in DxPx US.

Conventional phase 3 trials do not provide key information about the overall effect of introducing a new tuberculosis vaccine programme and so are missing crucial information for policy makers, argue experts in a personal view in Lancet Microbe.

PBD Biotech is one of the companies represented at a parliamentary reception organised by the British In Vitro Diagnostics Association (BIVDA)

The Inv€$tival Showcase in Old Billingsgate, London, is part of Europe’s biggest healthcare investment week. It will feature Actiphage TB, a groundbreaking diagnostic for tuberculosis.